.Attribute Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ sophisticated breast cancer and also active or even stable brain metastases presented consistent intracranial activity as well as wide spread efficiency of T-DXd.